Previous 10 | Next 10 |
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe PR Newswire InMed's Michael Woudenberg , Karen Long & Prof. Mauro Maccarrone among Expert Speakers VANCOUVER, BC , Jan. 19, 2021 ...
InMed Pharmaceuticals (INM) perks 5% premarket in reaction to the announcement of top-line results from its 755-102-HV Phase 1 clinical trial. Results indicate that INM-755 cream was safe and well-tolerated on induced open epidermal wounds, caused no delay in wound he...
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects PR Newswire TSX: IN NASDAQ: INM VANCOUVER, BC , Jan. 8, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: I...
InMed to Participate at Virtual Conferences in January 2021 Canada NewsWire VANCOUVER, BC , Jan. 5, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targ...
Lizhi (LIZI) +29%.Ekso Bionics Holdings (EKSO) +25%.AgEagle Aerial Systems (UAVS) +22%.ENGlobal Corporation (ENG) +23%.Supernus Pharmaceuticals (SUPN) +23%.Scopus BioPharma (SCPS) +21%.Mogo (MOGO) +18%.Magnite (MGNI) +18%.Kopin Corporation (KOPN) +18%.Magna International (MGA) +18%.InMed Phar...
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids TSX:IN NASDAQ:INM - Initial application with INM-088 to treat ocular disease - VANCOUVER, BC , Dec. 3, 2020 /CNW/ - InMed Pharmaceuticals Inc. ...
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects Canada NewsWire VANCOUVER, BC, Nov. 25, 2020 VANCOUVER, BC , Nov. 25, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX:...
InMed Announces Election of Directors Canada NewsWire VANCOUVER, BC, Nov. 24, 2020 VANCOUVER, BC , Nov. 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medica...
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics PR Newswire VANCOUVER, BC, Nov. 18, 2020 VANCOUVER, BC , Nov. 18, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Co...
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering PR Newswire VANCOUVER, BC, Nov. 16, 2020 VANCOUVER, BC , Nov. 16, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-st...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...